We showed that the pharmacological induction of PGC-1α and HO-1 as well as adipocyte-specific HO-1 overexpression ameliorates NAFLD and NASH in obese mice [9,26,57,58,59]. Here, PPARGC1A is linked to metabolic dysfunction-associated steatotic liver disease.